Inhibition of platelet function with clopidogrel, as measured with a novel whole blood impedance aggregometer in horses.
Authors: Roscher Katja A, Failing Klaus, Moritz Andreas
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary: Clopidogrel Dosing and Platelet Function in Horses Researchers validated a practical oral clopidogrel regimen for equine use by measuring platelet inhibition in ten Warmblood horses using whole blood impedance aggregometry—a technique that directly assesses platelet responsiveness in undiluted blood samples. A loading dose of 6–6.5 mg/kg followed by maintenance doses of 1.2–1.4 mg/kg daily for four days achieved rapid and sustained inhibition of ADP-mediated platelet aggregation (P < 0.01) and arachidonic acid-induced aggregation (P < 0.05 after 192 hours), whilst collagen-induced aggregation remained unaffected. Notably, platelet function recovered by day six post-treatment when measured against ADP stimulation, though inhibition persisted with arachidonic acid testing—suggesting horses may have different platelet activation mechanisms than humans. For equine practitioners managing conditions requiring antiplatelet therapy (such as certain thrombotic or prothrombotic states), this study provides evidence-based dosing parameters and demonstrates that clopidogrel's effects are both reliably achievable and reversible within a clinically manageable timeframe, though individual monitoring through aggregometry testing would be prudent for therapeutic confirmation.
Read the full abstract on PubMed
Practical Takeaways
- •Clopidogrel dosing of 6-6.5 mg/kg loading followed by 1.2-1.4 mg/kg daily maintenance is effective for platelet inhibition in horses and achieves therapeutic effect within hours
- •Prolonged platelet inhibition persists beyond medication cessation in horses compared to humans, which may require consideration in perioperative planning or when discontinuing therapy
- •This dosing scheme and monitoring method provides veterinarians a validated approach for managing thrombotic conditions in equine patients, though clinical efficacy in disease states remains to be demonstrated
Key Findings
- •Loading dose of 6-6.5 mg/kg clopidogrel induced rapid platelet inhibition within hours in horses
- •Maintenance dose of 1.2-1.4 mg/kg daily sustained platelet inhibition over 4 days of therapy
- •Significant inhibition achieved in ADP-induced and arachidonic acid-induced aggregation (P<0.01), but not collagen-induced aggregation
- •Platelet function recovery occurred 6 days post-medication for ADP tests, but remained inhibited with arachidonic acid test, suggesting species-specific differences from humans